Effects of anamorelin on microbiota

An observational study to explore the effects of anamorelin on gut microbiota in patients with carcinoma in situ with cachexia - ACADEMIC study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047574

Enrollment

Registered

2022-05-01

Start date

2022-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer cachexia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-small cell lung cancer, pancreatic cancer, gastric cancer, or colorectal cancer With at least 5% weight loss and loss of appetite within 6 months, 1) Fatigue or malaise 2) Generalized muscle weakness 3) Two or more of CRP>0.5mg/dL, Hb<12g/dL, ALB<3.2g/dL ECOG-PS 0-2 Patients with consent of the study

Exclusion criteria

Exclusion criteria: Patients with a prognosis of 12 weeks or less Previous anamorelin administration Patients with concomitant severe cardiac disease Hepatic dysfunction (Child-Pugh B or C) Difficulty with oral intake due to organic abnormalities (e.g. obstruction) of the gastrointestinal tract Other patients who are deemed inappropriate by the principal investigator

Design outcomes

Primary

Measure	Time frame
Changes in the diversity of intestinal microbiota before and after anamorelin administration	—

Secondary

Measure	Time frame
Change in body weight Percent change in EORTC-QLQ-C15PAL score Percent change in appetite-related items in EORTC-QLQ-C15PAL score	—

Countries

Japan

Contacts

Public ContactShogen Boku

Kansai Medical University Hospital Cancer Treament Center

shogen0820@gmail.com0728040101

Outcome results